Search by Algolia
Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
U.S. GoldMining Inc.U.S. GoldMining Reports $8.5 Million Net Loss for Fiscal Year 2024
CV Sciences, Inc.CV Sciences Reports Slight Decline in Sales, Strategic Acquisitions and New Product Launches
ASPAC II Acquisition Corp.ASPAC II Acquisition Corp. Reports Significant Net Income Decline and Faces Delisting Challenges
bluebird bio, Inc.bluebird bio Reports Revenue Growth to $83.8 Million Amid Increased Gene Therapy Infusions
TherapeuticsMD, Inc.TherapeuticsMD Reports Improved Net Loss and Increased License Revenue for Fiscal Year 2024
GSR III Acquisition Corp.GSR III Acquisition Corp. Reports Financial Performance for Fiscal Year Ending December 31, 2024
BIO-PATH HOLDINGS INCBio-Path Holdings Reports $9.9 Million Net Loss for Fiscal Year 2024
VirTra, IncVirTra Reports 32% Revenue Decline to $26.4 Million for Fiscal Year 2024
RELMADA THERAPEUTICS, INC.Relmada Therapeutics Reports Decreased Net Loss and Strategic Shift in Drug Development
Neuronetics, Inc.Neuronetics Reports 5% Revenue Increase to $74.9 Million, Faces $43.7 Million Net Loss
Acumen Pharmaceuticals, Inc.Acumen Pharmaceuticals Reports $102.3 Million Net Loss for 2024, Driven by Increased R&D Expenses
Tempest Therapeutics, Inc.Tempest Therapeutics Reports $41.8 Million Net Loss for Fiscal Year 2024
Linkhome Holdings Inc.Linkhome Holdings Inc. Reports 456% Revenue Growth to $7.62 Million in 2024
Clearside Biomedical, Inc.Clearside Biomedical Reports $34.4 Million Net Loss and Decreased Revenue for Fiscal Year 2024
ZION OIL & GAS INCZion Oil & Gas Reports $7.34 Million Net Loss for Fiscal Year 2024, Receives New Exploration License
Pony Group Inc.Pony Group Inc. Reports 45% Revenue Decline and Net Loss for Fiscal Year 2024
SK Growth Opportunities CorpSK Growth Opportunities Corp. Reports $3.2M Net Income for 2024, Signs Business Combination Agreement with Webull
Spero Therapeutics, Inc.Spero Therapeutics Reports $68.6 Million Net Loss for 2024, Decreased Collaboration Revenue
FACT II Acquisition Corp.FACT II Acquisition Corp. Reports No Revenue and $71,891 Net Loss for Fiscal Year Ending December 31, 2024
Texas Community Bancshares, Inc.Texas Community Bancshares Reports $1.3 Million Net Loss for Fiscal Year 2024
Tyra Biosciences, Inc.Tyra Biosciences Reports $86.48 Million Net Loss for 2024, Increases R&D Spending
Gain Therapeutics, Inc.Gain Therapeutics Reports $20.4 Million Net Loss for Fiscal Year 2024, No Revenue Generated
IRIDEX CORPIRIDEX Corporation Reports $48.7 Million Revenue and $8.9 Million Net Loss for Fiscal Year 2024
NEXTNRG, INC.NextNRG Reports $16.2 Million Net Loss Despite 19.6% Revenue Growth in 2024
Kodiak Sciences Inc.Kodiak Sciences Reports $176.2 Million Net Loss for 2024, Decreased R&D Expenses